Hide metadata

dc.date.accessioned2022-02-15T16:45:55Z
dc.date.available2022-02-15T16:45:55Z
dc.date.created2022-01-25T11:36:54Z
dc.date.issued2021
dc.identifier.citationKaustio, Meri Nayebzadeh, Naemeh Hinttala, Reetta Tapiainen, Terhi Åström, Pirjo Mamia, Katariina Aino Inkeri Pernaa, Nora Lehtonen, Johanna Marianna Glumoff, Virpi Rahikkala, Elisa Honkila, Minna Olsén, Päivi Hassinen, Antti Polso, Minttu Al Sukati, Nashat Al Shekaili, Jalila Al Kindi, Mahmood Al Hashmi, Nadia Almusa, Henrikki Bulanova, Daria Haapaniemi, Emma Maria Chen, Pu Suo-Palosaari, Maria Vieira, Paivi Tuominen, Hannu Kokkonen, Hannaleena Al Macki, Nabil Al Habsi, Huda Löppönen, Tuija Rantala, Heikki Pietiäinen, Vilja Zhang, Shen-Ying Renko, Marjo Hautala, Timo Al Farsi, Tariq Uusimaa, Johanna Saarela, Janna Saija . Loss of DIAPH1 causes SCBMS, combined immunodeficiency, and mitochondrial dysfunction. Journal of Allergy and Clinical Immunology. 2021
dc.identifier.urihttp://hdl.handle.net/10852/90982
dc.description.abstractBackground Homozygous loss of DIAPH1 results in seizures, cortical blindness, and microcephaly syndrome (SCBMS). We studied 5 Finnish and 2 Omani patients with loss of DIAPH1 presenting with SCBMS, mitochondrial dysfunction, and immunodeficiency. Objective We sought to further characterize phenotypes and disease mechanisms associated with loss of DIAPH1. Methods Exome sequencing, genotyping and haplotype analysis, B- and T-cell phenotyping, in vitro lymphocyte stimulation assays, analyses of mitochondrial function, immunofluorescence staining for cytoskeletal proteins and mitochondria, and CRISPR-Cas9 DIAPH1 knockout in heathy donor PBMCs were used. Results Genetic analyses found all Finnish patients homozygous for a rare DIAPH1 splice-variant (NM_005219:c.684+1G>A) enriched in the Finnish population, and Omani patients homozygous for a previously described pathogenic DIAPH1 frameshift-variant (NM_005219:c.2769delT;p.F923fs). In addition to microcephaly, epilepsy, and cortical blindness characteristic to SCBMS, the patients presented with infection susceptibility due to defective lymphocyte maturation and 3 patients developed B-cell lymphoma. Patients’ immunophenotype was characterized by poor lymphocyte activation and proliferation, defective B-cell maturation, and lack of naive T cells. CRISPR-Cas9 knockout of DIAPH1 in PBMCs from healthy donors replicated the T-cell activation defect. Patient-derived peripheral blood T cells exhibited impaired adhesion and inefficient microtubule-organizing center repositioning to the immunologic synapse. The clinical symptoms and laboratory tests also suggested mitochondrial dysfunction. Experiments with immortalized, patient-derived fibroblasts indicated that DIAPH1 affects the amount of complex IV of the mitochondrial respiratory chain. Conclusions Our data demonstrate that individuals with SCBMS can have combined immune deficiency and implicate defective cytoskeletal organization and mitochondrial dysfunction in SCBMS pathogenesis.
dc.languageEN
dc.publisherAmerican Academy of Allergy, Asthma and Immunology
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleLoss of DIAPH1 causes SCBMS, combined immunodeficiency, and mitochondrial dysfunction
dc.typeJournal article
dc.creator.authorKaustio, Meri
dc.creator.authorNayebzadeh, Naemeh
dc.creator.authorHinttala, Reetta
dc.creator.authorTapiainen, Terhi
dc.creator.authorÅström, Pirjo
dc.creator.authorMamia, Katariina Aino Inkeri
dc.creator.authorPernaa, Nora
dc.creator.authorLehtonen, Johanna Marianna
dc.creator.authorGlumoff, Virpi
dc.creator.authorRahikkala, Elisa
dc.creator.authorHonkila, Minna
dc.creator.authorOlsén, Päivi
dc.creator.authorHassinen, Antti
dc.creator.authorPolso, Minttu
dc.creator.authorAl Sukati, Nashat
dc.creator.authorAl Shekaili, Jalila
dc.creator.authorAl Kindi, Mahmood
dc.creator.authorAl Hashmi, Nadia
dc.creator.authorAlmusa, Henrikki
dc.creator.authorBulanova, Daria
dc.creator.authorHaapaniemi, Emma Maria
dc.creator.authorChen, Pu
dc.creator.authorSuo-Palosaari, Maria
dc.creator.authorVieira, Paivi
dc.creator.authorTuominen, Hannu
dc.creator.authorKokkonen, Hannaleena
dc.creator.authorAl Macki, Nabil
dc.creator.authorAl Habsi, Huda
dc.creator.authorLöppönen, Tuija
dc.creator.authorRantala, Heikki
dc.creator.authorPietiäinen, Vilja
dc.creator.authorZhang, Shen-Ying
dc.creator.authorRenko, Marjo
dc.creator.authorHautala, Timo
dc.creator.authorAl Farsi, Tariq
dc.creator.authorUusimaa, Johanna
dc.creator.authorSaarela, Janna Saija
cristin.unitcode185,57,19,0
cristin.unitnameSaarela group - Human immune disorders
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin1989338
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal of Allergy and Clinical Immunology&rft.volume=&rft.spage=&rft.date=2021
dc.identifier.jtitleJournal of Allergy and Clinical Immunology
dc.identifier.volume148
dc.identifier.issue2
dc.identifier.startpage599
dc.identifier.endpage611
dc.identifier.doihttps://doi.org/10.1016/j.jaci.2020.12.656
dc.identifier.urnURN:NBN:no-93573
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0091-6749
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/90982/1/1-s2.0-S0091674921003456-main.pdf
dc.type.versionPublishedVersion
dc.relation.projectNFR/187615


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International